Changing the Market for Orals: the Exubera Challenge
This article was originally published in RPM Report
Executive Summary
Investors are betting that the new inhaled insulin, Exubera, will simply take share from existing insulins. But managed care groups might prefer, given Exubera's likely cost and medical benefits, that it take share from the most expensive orals, the glitazones Avandia and Actos.